Actions Panel
If you build it will they come? Biotech 2.0
When and where
Date and time
Thursday, May 2, 2013 · 5:30 - 9pm EDT
Location
The Broad Institute 415 Main St Cambridge, MA 02142
Description
“If you build it will they come? Biotech 2.0”
Date & Location
May 2, 2013
The Broad Institute
Event Description
Do I launch my biotech startup confident that its great idea will catch on and become successful according to the wisdom of the marketplace? Do I start out with a fully conceived exit strategy and make all decisions based on that?
Funding biotech companies has probably never been harder than it is today. The old model of the highly capitalized fully-integrated bricks and mortar biotech with a concept that raises millions dollars in venture funding on its way to going public is a thing of the past.
VC’s have less capital, capital is more expensive, M&A and option deals are often negotiated before investors will invest and IPO’s are no longer the likely exit.
Today, angels are more active and are investing in therapeutic companies, VC’s are looking for lower risk bigger opportunities, and big pharma are playing a larger role in exits and early stage fundings– so come listen to our panel of experts on the latest ideas on how you should set up, manage, partner and fund a new biotech venture today to best ensure “if you build it, they will come.”
Agenda
5:30-6:30pm: Cocktails, Hors d'oeuvres and Networking
6:30-8:00pm: Panel Discussion
8:00-9:00pm: Networking
Moderator
Marc Cote, COO of Accellient Partners, CFO of Synchroneuron Inc. and member of Boston Harbor Angels
Panel
- Therapeutic Angel Investor – Rob Manning, Co-Chair of Cherrystone Angels
- Venture Capitalist – Alexis Borisy, Partner, Third Rock Ventures
- Strategic Pharma Executive – Mark Day, PhD, Global Lead for CNS Search and Evaluation in the Strategic Transactions Group at Bristol Myers Squibb
- Serial Entrepreneur – Ben Bronstein, Serial Founder/CEO, Visiting Scholar at Wyss Institute for Biologically Inspired Engineering, and Principal at Cold Spring Venture Advisors
-
Corporate Venture - Brian Gallagher, Partner, SR One Ltd
The Bioscience Network (TBN)
Where you are the future of life sciences
Have questions about this event?
Contact info@thebiosciencenetwork.org